In order to overcome serological cross-reactions among orbivirus serogroups, which can hinder the accurate diagnosis of bluetongue virus (BTV) infection of livestock, a blocking ELISA (B-ELISA) incorporating a monoclonal antibody (20E9B7G2) with specificity for the BTV serogroup was developed. Experimental antisera raised to South African BTV serotypes 1 to 19 were tested in the B-ELISA and all blocked the binding of 20E9B7G2 to BTV antigen. The sensitivity and specificity of the assay was evaluated with a range of experimental and field sera and compared to a sensitive indirect ELISA (I-ELISA) for the detection of BTV-specific antibodies. The specificity of the B-ELISA was absolute for antibodies to BTV, showing no cross-reaction with experimental antisera to serotypes of the closely related orbivirus causing epizootic haemorrhagic disease of deer. The sensitivity of the B-ELISA exceeded that of the I-ELISA. In particular, the B-ELISA detected a BTV-specific antibody response much earlier after infection that the I-ELISA, while still exhibiting full sensitivity to BTV antibody titres several months after infection.
INTRODUCTION
Bluetongue virus (BTV) is a member of the orbivirus genus in the Reoviridae family (Murphy et al., 1971) . The bluetongue group is defined serologically by the agar gel diffusion precipitin (AGDP) test and also by complement fixation (Jochim & Chow, 1969; Boulanger & Frank, 1975) . However, division into serogroups is not absolute, with inter-group reactivity observed between BTV and several other of the groups comprising the genus (Moore, 1974; Della-Porta et al., 1983a) . In particular, the viruses of epizootic haemorrhagic disease of deer (EHD), the Palyam and Eubenangee serogroups have been shown to be serologically related to BTV. This is a major impediment to the specificity of assays for the detection of antibody to BTV. Immunological cross-reaction between BTV and EHD is seen with a number of virus-specified proteins (Huismans & Els, 1979; Appleton & Letchworth, 1983) . The major group-reactive core protein for BTV, VP7, and to a lesser extent the core protein VP3 appear to share immunogenic regions between BTV and EHD . It may therefore be impossible for any serological assay that measures unrestricted binding of polyclonal test sera to an antigen preparation containing several virus-specified proteins to avoid the problems of crossreactivity. An indirect ELISA (I-ELISA) which we have developed (Lunt et al., 1987) , while more sensitive and specific than currently adopted serological tests, still encountered some problems with cross-reactivity with other orbiviruses. In addition, difficulties in purifying BTV from cellular protein can lead to significant background reactivity in the ELISA (Hubschle, 1982) . A method for a competition ELISA where BTV-specific antibodies present in test antisera actively blocked the binding of a BTV group-specific monoclonal antibody (MAb) has been reported (Anderson, 1984) . However this assay was evaluated against a restricted range of field sera, and only a limited investigation of its specificity with regard to potential crossreactions with the closely related orbivirus EHD was undertaken. This paper describes the 0000-8259 © 1988 SGM establishment of a blocking ELISA (B-ELISA) which has been tested using hyperimmune experimental antisera to six BTV and five EHD serotypes from Australia and antisera to a range of BTV serotypes from South Africa. The diagnostic potential of the assay was evaluated by screening a large number of field sera with antibody responses to BTV and EHD, and comparing these results with those of an established I-ELISA for BTV antibody detection (Lunt et al., 1987) . In addition, we have investigated the sensitivity of the B-ELISA for the detection of antibodies many months after infection and also studied its sensitivity during the acute phase of infection. The latter study was essential for the determination of an accurate negative 'cut-off' value for this assay.
METHODS
Viruses. The following viruses were used: an attenuated vaccine strain of South African BTV serotype 1 (BTV 1) (supplied by the Commonwealth Serum Laboratories, Parkville, Australia), and Australian isolates of BTV1 (CSIRO156), BTV15 (DPP192) and EHD (Ibaraki) (CSIRO439) which were originally provided by the Northern Territory Department of Primary Produce (DPP) and the CSIRO Division of Tropical Animal Science, Longpocket, Queensland, Australia.
Virus propagation. BTV was grown in Veto cells and viral antigen was processed to produce freeze-thawed (F/T) and P200 preparations (Lunt et al., 1987) .
Antisera. Experimental antisera produced in cattle to Australian BTV and EHD serotypes were prepared as previously described (Lunt et al., 1987) . Post-infection (p.i.) serial bleeds of bovine and ovine antisera to Australian BTV serotypes resulted from earlier studies (Parsonson et al., 1987; Della-Porta et al., 1983a) . Inactivated ovine and guinea-pig antisera to South African BTV serotypes were obtained from the Commonwealth Serum Laboratories, ParkviUe, Australia. Field sera were collected from cattle and goats in northern Australia and supplied to this laboratory by the Northern Territory DPP and the CSIRO Division of Tropical Animal Science.
MAb production and screening. BALB/c mice were inoculated with a P200 antigen preparation of BTV1 (CSIRO156) and their spleen lymphocytes fused to Sp2/0-Ag-14 myeloma cells in a 5:1 ratio as described elsewhere (Eaton et aL, 1987) . Hybridoma cell culture supernatants producing BTV-specific MAb were screened for use in the B-ELISA. PVC microtitre plates (Cooke's Dynatech, Alexandria, Va., U.S.A. ; cat. no. 1-220-24) were coated with a P200 preparation of BTV1 (CSIRO156). Fifty I~l of immune bovine sera to BTV1 (CSIRO156), BTV20 (CSIRO19), EHD (CSIRO439) and a negative control serum were added to successive columns of the plate at an optimum dilution in 0-01 x-phosphate-buffered saline pH 7-2 containing 0.05% Tween 20 (PBST). After 1 h incubation at 37 °C plates were washed five times for 30 s in PBST and 50 p.1 of hybridoma cell culture supernatant diluted 1/4 in PBST was added to each well. After 1 h at 37 °C, plates were washed and 50 btl of an appropriately diluted goat anti-mouse IgG-horseradish peroxidase (HRPO) affinity-purified conjugate (KPL, Gaithersburg, Md., U.S.A. ; cat. no. 14-18-06) in PBST was added. After a further 1 h incubation at 37 °C and washing step, 50 p.1 of the substrate, 0.006~ (w/v) n20 2 and 0.08~ (w/v) o-phenylenediamine (BDH) in 0.1 M-citrate-phosphate buffer pH5-0, was added. The reaction was stopped after 10 min at room temperature using 1 M-H2SO4. Plates were read at 492 nm on a Titertek Multiskan ELISA plate reader (Flow Laboratories). Percentage inhibition levels in wells containing immune serum relative to the negative serum were calculated for all hybridoma supernatants tested.
I-ELISA. The I-ELISA was performed as previously described (Lunt et al., 1987) , with the following modifications. A mixture of BTVI (CSIRO156) and BTVl5 (DPPI92) F/T antigens in a ratio (1:10), predetermined by earlier chequerboard titration with reference antisera to each serotype, was bound to the microtitre tray. Sheep anti-bovine and donkey anti-ovine/caprine-HRPO conjugates (Silenus, Victoria, Australia) were used. The substrate was 42 mM-3,Y,5,5',-tetramethylbenzidirte (TMB) (Sigma) plus 0.001 ~ (w/v) H20 2 in citrate-acetate buffer pH 6.0 (Bos et al., 1981) . The reaction was stopped with 1 M-H~SO4 and plates were read at 450 nm in a Titertek Multiskan plate reader. Sera diluted 1/100 were tested on mock infection and viral antigen and results calculated as net specific absorbance. An EHD-specific I-ELISA was performed similarly using the EHD isolate CSIRO439 as viral antigen (Lunt et al., 1987) .
B-ELISA. PVC microtitre plates (see above) were coated with 100 izl per well of a mixture of BTV1 (CSIRO156) and BTV15 (DPP192) virus antigen, at a ratio predetermined as for the I-ELISA, in 0.05 M-Tris-HC1 pH 9.5. Fifty ktl portions of test sera diluted 1/10 in 0.01 M-PBST pH 7.2 were added in duplicate to plate wells and incubated for 1 h at 37 °C with shaking. Three negative control sera and a homologous bovine reference antiserum was included on each plate to provide the zero inhibition baseline level and positive control respectively.
Fifty ~tl of MAb purified from mouse ascites fluid by affinity chromatography on a Protein A-Sepharose CL-4B column (Pharmacia) by the method of Ey et al. (1978) , was added to the serum in the wells at a previously determined optimum dilution in PBST (i.e. there was no washing step between the addition of the sera and the MAb dilutions to the plate). Plates were then returned to 37 °C for 1 h with shaking. The plates were washed, and Blocking ELISA for antibodies to BTV 2731 40 ktl of an afffinity-purified sheep anti-mouse IgG-HRPO conjugate (Silenus, cat. no. DAH) diluted in PBST was added. This was incubated for 1 h at 37 °C with shaking, followed by a washing step and the addition of TMB substrate as for the I-ELISA. Percentage inhibition levels were calculated relative to the mean absorbance of the three negative control sera, as follows: percentage inhibition = 100-[100 x (absorbance of test serum/ absorbance of negative control)]. Sucrose densityfractionation ofsera. Sera were fractionated in 2.0 ml 10 to 40~ sucrose gradients. Sera were diluted fourfold in 0.15 M-NaC1, 10 mM-Tris-HC1, 1-5 mM-EDTA buffer and 0-4 ml was layered onto the gradient. Tubes were centrifuged in an SW55 rotor (Beckman) at 10 °C for 5 h at 50000 r.p.m. Fractions were collected from the bottom of the tube in 300 ~tl volumes and tested at a 50~ dilution in the B-ELISA.
Radioimmunoprecipitation assay. This assay utilized the method of Appleton & Letchworth (1983) , with the following modifications. BHK or Vero cells were infected with BTV1 at an m.o.i, of 3 p.f,u./ml and subsequently labelled with 250 ~tCi/ml of [35S]methionine (Amersham) at 16 to 18 h p.i. Infected cells were maintained at 32 °C before labelling, to inhibit host protein production. Lysis buffer consisted of 0.05 M-NaC1, 2 mM-EDTA, 0.05 MTris-HC1 pH 7.0, 5 mM-PMSF, 0.5~ sodium deoxycholate and 1~ Triton X-100. Lysates were clarified at 20000 r.p.m, for 2 h and pre-cleared once with Staphylococcus aureus bearing Protein A (Sigma). Pre-cleared lysate (100 ~tl) was added to MAb solution (100 ~tl), incubated at room temperature for 1 h and precipitated with 25 ~tl of packed S. aureus bearing Protein A per 200 ktl of total reaction volume. Immune complexes were eluted with sample buffer and run on a 10~ discontinuous SDS-polyacrylamide gel (Laemmli, 1970) .
RESULTS

Screening of MAbs
A collection of MAbs to BTV1 (CSIRO156) were screened in the BTV and EHD I-ELISA. BTV-specific hybridoma supernatants (a total of 169) were then screened for reactivity in the B-ELISA. Only a small number (19) of these were also sensitive to blocking with antiserum to BTV20 (CSIRO19) and only seven of this group were strongly blocked. MAb 20E9B7G2 (isotype IgG2a), which specifically immunoprecipitated the major core protein VP7 (results not shown), was twice cloned by limiting dilution and further tested as a potentially suitable reagent for the B-ELISA.
BTV 1-ELISA Significant antigenic differences have been noted between BTVI5 (DPP192) and other Australian BTV serotypes (Gould, 1987; Della-Porta et al., 1983 b) . In order to ensure that the I-ELISA for comparison with the B-ELISA had a broad reactivity throughout the BTV serogroup, the combining of a BTV15 antigen with the BTV1 antigen preparation normally employed in this test was investigated. There is a significant one-way cross-reaction between sera to BTV1 and BTV15. Sera to BTV15 react poorly with BTV1 (CSIRO156) F/T antigen, but sera to BTV1 (CSIRO156) react well with both preparations (Fig. 1 ). For subsequent I-ELISA screening of experimental and field sera, plates were coated with a mixture of these two antigens in a ratio predetermined by chequerboard titration.
B-ELISA
To improve the B-ELISA for use in screening experimental and field sera, several modifications were made to the method used for screening hybridoma supernatants for sensitivity to blocking. The washing step between the test serum binding and addition of MAb was abandoned when it was found that a significant improvement could be obtained by the addition of the diluted MAb directly to the diluted serum volume (Fig. 2) . Other modifications included the use of the easily prepared F/T antigen and the use of a sheep anti-mouse IgG-HRPO conjugate and TMB as substrate, which resulted in increased test sensitivity.
Bovine antisera raised to BTV1 (CSIRO156), BTV 15 (DPP 192) and BTV20 (CSIRO19) were tested at different dilutions in the B-ELISA (Fig. 2 ). Antisera to BTV1 and BTV20 strongly inhibited the binding of 20E9B7G2; however, antiserum to BTV15 was much less efficient. To improve the ability of BTV15-specific antiserum to block 20E9B7G2, an optimum coating antigen ratio of BTV15 and BTV1 was determined which resulted in improved blocking of BTV15 antiserum without significantly affecting the blocking ability of antisera to other BTV serotypes (Table 1) tested and titrated in the modified B-ELISA (Table 2 ). All sera exhibited significant blocking ability at a 1/10 dilution. However, the titration endpoints at 40~ inhibition of 20E9B7G2 binding varied extensively. Antiserum to South African BTV serotypes BTV3, and to Australian BTV 15 displayed relatively low blocking titres. Guinea-pig reference antisera to BTV6 and BTV7 displayed good blocking levels for the former serotype but relatively poor levels for the latter. Interestingly the converse was found for these two serotypes when ovine reference antisera was used. All of the remaining Australian BTV serotypes tested had strong blocking titres.
In determining suitable MAbs for use in the B-ELISA we found an extensive time course analysis of the immune response to be extremely important. Thus the ability of the B-ELISA to detect persistent antibody levels in animals following a single BTV inoculation was examined by testing sera from cattle, taken over a period of 120 days after inoculation with BTV20 (CSIRO19). Several MAbs that had shown promise as suitable reagents for the assay on initial screening failed to exhibit sensitivity to blocking throughout the duration of the immune response to initial BTV infection. For example, antisera from eight animals (bovine) receiving a single inoculation of BTV20 persistently blocked the binding of MAb 20E9B7G2 but showed a rapidly declining ability to block a second MAb, 7C1 l/A1, beyond approximately 50 days p.i. The results for one such animal are shown in Fig. 3 , together with the levels seen in the I-ELISA. The B-ELISA, incorporating 20E9B7G2, was found to be highly sensitive, with levels of detectable antibody rising rapidly from 15 to 20 days p.i. and stabilizing at high levels. 1  78  690  99  380  2  86  300  100  800  3  86  70  64  40  4  82  500  99  300  5  79  150  81  60  6  77  280  83  60  7  84  50  100  750  8  86  620  100  700  9  84  330  100  600  10  90  760  100  900  11  97  590  100  800  12  85  410  100  350  13  87  200  81  80  14  90  150  61  60  15  88  50  NA~  -16  90  80  NA  -17 The B-ELISA and I-ELISA showed almost identical sensitivity to absolute amounts of IgG present in a hyperimmune antiserum to BTV1 (CSIRO156) (Fig. 4) . However, the former detected rising antibody levels before the latter (Fig. 3) , which suggested the B-ELISA was sensitive to IgM class antibody. To investigate this question, acute and convalescent phase sera were fractionated by sucrose gradient centrifugation and tested in the B-ELISA. This showed that the assay was sensitive to the presence of rising IgM levels early in infection in addition to lower levels of IgG (Fig. 5) .
IP
For the initial screening of hybridoma supernatants by the B-ELISA, possible cross-reactivity of EHD antisera was monitored by including an antiserum to EHD strain CSIRO439. The results of testing a range of experimental antisera to other Australian EHD isolates are shown in Table 3 . High levels of inhibition were seen with antisera to three strains, DPP59, CSIROI57 and CSIRO753. However, significant variation between animals was also apparent for antisera to two of these isolates, indicating some non-specific factor may have caused blocking of 20E9B7G2 for antisera from animals V16 and V36. As previously described (Lunt et al., 1987) , experimental antisera used in this study were raised to viral antigen derived from inoculation of suckling mouse brains. We hypothesized that the blocking observed for antiserum from animals V 16 and V36 may have been due to mouse immunoglobulin or certain other host protein(s) in the original inoculum that elicited antibodies capable of complexing with, or interfering with the binding of 20E9B7G2 to, viral antigen trapped on the ELISA plate. To investigate this we adsorbed both BTV-and EHD-specific antisera against a 1 ~ (final concentration) suspension of normal suckling mouse brain material before reaction in the B-ELISA. Adsorption resulted in a dramatic reversal of severe or partial blocking of 20E9B7G2 by EHD antisera, but did not significantly affect the blocking ability of BTV antisera (Table 4) . To assess further the B-ELISA for its sensitivity and specificity for antibodies to BTV, and to determine an appropriate negative 'cut-off' value, 166 bovine and 40 ovine experimental antisera to Australian BTV and EHD serotypes were tested in the I-ELISA and the B-ELISA, and the results were plotted against one another (Fig. 6a) . In the B-ELISA there was a relatively tight clustering of results for negative and positive antisera. The negative 'cut-off' value was determined at the level of 40~o inhibition of binding of 20E9B7G2, this being the level at which the highest negative value approached the lowest positive value. The I-ELISA 'cut-off' value of 0.26 absorbance units was determined in a previous study (Lunt et al., 1987) and remained appropriate on the basis of the results gained here. In Fig. 6(a) , bleeds taken in the acute phase of infection at 10 and 17 days p.i. are distinguished. In addition, those samples which would have been deemed positive in the I-ELISA based upon their absolute absorbance reading but made negative when corrected for their absorbance level on mock antigen (net absorbance) are also shown. Of the 17 antisera that were positive by the B-ELISA but negative in the I-ELISA, nine were bleeds taken during the acute phase of infection, further demonstrating the increased sensitivity of the B-ELISA during early infection. Four sera were positive by absolute absorbance values in the I-ELISA but negative when their mock antigen absorbance values were accounted for (one of these sera was also a day 10 acute phase bleed). The remaining five sera of the B-ELISA-positive, I-ELISAnegative group did not fall into either of the previous two categories. All of these sera were taken from BTV-infected animals. It could therefore be concluded that the B-ELISA was exhibiting greater sensitivity than the I-ELISA to very low levels of BTV-specific antibodies present in these bleeds. Field sera (178 bovine and 122 caprine) were tested in the B-ELISA and I-ELISA and the results were compared (Fig. 6b) . Sera tested in the I-ELISA that were positive by their absolute absorbance on specific antigen, but negative when corrected for their mock antigen reaction were distinguished, and comprised 32 samples. Twenty-nine of these formed part of the B-ELISA-positive, I-ELISA-negative group, which, as was apparent with the analysis of experimental antisera (Fig. 6a) , highlights the problems of accurately differentiating separate test serum titres to specific and mock antigenic determinants, especially where the specific reaction is very weak. The greater spread of percentage inhibition values in the B-ELISA for field sera, compared to experimental antisera, reflects the wider range of specific antibody levels present in the field situation. A further 65 sera were positive in the B-ELISA but negative in the I-ELISA. The amount of disagreement between the two assay systems was therefore 94/300 (approx. 31 ~). To determine whether this'level of discrepancy between the tests reflected an increased sensitivity for the B-ELISA or a decreased specificity, the 94 sera in question were tested in the EHD I-ELISA against EHD2 (CS439) and analysed at the level of the individual herds from which the sera had been collected (Table 5) . Five herds (A, C, D, E and G) exhibited a level of EHD activity significantly higher than the 16 ~ level found in the B-ELISA-negative, BTV I-ELISA-negative sera as determined by the EHD I-ELISA. In total, 36~o of the 94 B-ELISA-positive, BTV I-ELISA-negative sera had titres to EHD. A large proportion of these sera (approx. 22~) were from herd C. Two of the field sera tested were positive in the BTV I-ELISA and negative in the B-ELISA. DISCUSSION We have established a B-ELISA for detection of antibodies to BTV and examined its performance with a wide range of field and experimental antisera. From a large panel of hybridoma supernatants screened for suitability in the B-ELISA, relatively few were acceptable. Several factors may have contributed to this. The supernatants screened were mainly from uncloned hybridoma cell lines, and a mixture of two BTV-specific MAbs, only one of which is blocked, will produce a negative result in the B-ELISA. At the screening stage, plates were washed before the addition of hybridoma supernatants. We have shown that this is a less sensitive method than addition of a MAb preparation directly to the blocking serum dilution without washing (Fig. 2) . The later availability of a more highly specific anti-mouse immunoglobulin-HRPO conjugate eliminated earlier problems with non-specific background in the screening assay. However Anderson (1984) , using cell culture supernatant-derived BTV antigen to immunize mice for hybridoma fusions, also reported a low percentage of reactive MAbs that were suitable for use in a B-ELISA system. The hybridoma line 20E9G7B2 was found to produce MAb highly sensitive to blocking by serum antibody to BTV, and this was fully evaluated in the B-ELISA against a range of experimental and field sera (Tables 1, 2 and 5; Fig.  3 to 6) .
Reference antisera to all BTV serotypes tested effectively blocked the binding of 20E9B7G2 to BTV1 (CSIRO156) at a 1/10 dilution (Tables 1 and 2 ). Detectable genetic differences occur between the complement of BTV strains of different continents, perhaps reflecting divergent evolution due to geographic isolation (Spence et al., 1984; Gould, 1987) . This probably explains why the blocking ability of certain BTV serotypes (3, 5, 13, 14, 15, 16, 18 and 19) was weaker than others when expressed as an endpoint titre (Table 2 ). Antisera to all of the Australian BTV serotypes tested, with the exception of BTV15, had strong blocking titres (Table 1) . Anderson (1984) using the same set of guinea-pig reference antisera to BTV serotypes found a very similar relationship between individual serotypes and their ability to block the binding of a MAb raised to BTV1. However the equivalent 40~ endpoint titres for BTV7, BTV21 and in particular BTV19, were much lower than the results gained in this study. It may be that use of an Australian isolate of BTV1 (CSIRO156) initially to raise MAbs for use in the B-ELISA has enhanced the group-reactive potential of the assay.
The immunological differences between BTV15 (DPP 192) and other Australian BTV strains have been observed previously (Lunt et al., 1987; Della-Porta et al., 1983b) . That BTV15 (DPP192) actually belongs to the BTV serogroup has been demonstrated by the reactivity of antisera to this isolate with BTV1 (CSIRO156) when using the P200 antigen (Lunt et al., 1987) , by the one-way cross-reaction observed in this study (Fig. 1) and by studies of its genome (Gould, 1987) . Nevertheless, MAb 20E9B7G2 which binds to all other BTV serotypes available for testing (results not shown) does not bind BTV 15 (DPP 192) . The relatively inefficient blocking of 20E9B7G2 by antiserum to BTV 15 (DPP192) (Fig. 2) and the poor reactivity of this antiserum in the indirect ELISA employing a F/T BTV1 (CSIRO156) antigen alone ( Fig. 1 ) must indicate substantial antigenic differences between BTV 15 (DPP 192) and BTV1 (CSIRO156). However, the same antiserum exhibited acceptable blocking levels when BTV15 (DPP192) antigen was incorporated into the assay system. Presumably the binding of BTV15-specific antiserum to its homologous antigen results in either augmentation of the efficiency of binding of this antiserum to BTV1 antigen, or prevents the binding of 20E9B7G2 to BTV1 by steric hindrance.
It has been reported that the levels of antibodies to VP7 may decline with time after initial infection with BTV (Huismans & Erasmus, 1981) . We found little evidence of this for the VP7 epitope defined by 20E9B7G2 in eight cattle given a single inoculation of BTV20. The response of one of these is shown in Fig. 3 . However, the response to an epitope suspected to be on the other major viral core protein, VP3 (Eaton et al., 1987) as defined by a second MAb, 7C1 l/A1, did decline after initial infection. We found when testing for a suitable MAb to use in the B-ELISA that such an analysis of the immune response of an infected animal over a protracted time course was essential in determining the ultimate sensitivity of the test. As seen in Fig. 3 , MAb 7C 11/A 1 displayed equally good sensitivity to blocking compared to 20E9B7G2 relatively early after infection, but this sensitivity declined rapidly after approximately 50 days p.i. Therefore, when screening field animals with unknown infection histories, 20E9B7G2 is the more appropriate reagent to use to ensure efficient detection of serum titres to BTV. However MAbs such as 7C1 l/A1 with specificities for epitopes that generate a relatively short-lived immune response may be useful in detecting recent field infections. When testing the BTV B-ELISA for potential cross-reaction with EHD serotypes it was considered appropriate to test sera taken from EHD-inoculated animals up to 60 days p.i. to maximize the potential effects of any cross-reacting heterologous antibodies present (Della-Porta et al., 1985; Jeggo et al., 1983) on the assay (results not shown).
The testing of a large panel of experimental antisera to BTV indicated that the B-ELISA is highly sensitive (Fig. 6 a; Table 1 ). The problems encountered in the I-ELISA with BTV-specific antisera that also reacted non-specifically with mock antigen were eliminated in the B-ELISA (Fig. 6a) . Disparities between the B-ELISA and the I-ELISA may occur where a bleed is taken in the acute stage of infection (Fig. 6a) . However, of potential concern is the ability of some experimental antisera raised to particular EHD strains (i.e. DPP59, CS157 and CS753) in individual animals to block the binding of 20E9B7G2 in the B-ELISA (Table 3 ). The antisera in question were prepared using consecutive inoculations of mouse brain-adapted virus in addition to the initial use of Freund's complete adjuvant. The immune response under such a regime is not necessarily directly comparable to that resulting from natural infection in the field; also, antibody specific for some mouse-derived component may interfere non-specifically in the assay. However multiple infections with a variety of orbiviruses can occur in the field and may result in the development of a heterologous immune response to orbiviruses that the host animal has not actually encountered (Jeggo et al., 1983; Della-Porta et al., 1985) .
The ability of the EHD reference antiserum to produce a positive blocking result in the B-ELISA may have been a consequence of non-specific factors or due to the presence of crossreactive heterologous antibody. We investigated this by pre-adsorbing test antisera with a 1 suspension of normal suckling mouse brain before carrying out the assay procedure. This completely reversed the blocking effect of EHD antisera without affecting the blocking ability of BTV reference antisera (Table 4) .
The B-ELISA was found to be more sensitive than the I-ELISA for the detection of virusspecific antibody production early after initial infection ( Fig. 3 and 6a ). This was due to the greater effectiveness of virus-specific IgM in the B-ELISA system compared to the I-ELISA in the early stages of the immune response (Fig. 5) . Anderson (1984) and Afshar et al. (1987) have also commented on the increased sensitivity of BTV B-ELISA systems during early infection. They both found levels of blocking significantly greater than 40~ inhibition as early as 7 to 10 days p.i., which confirms the results in this study (Fig. 6a) .
When 300 bovine and caprine field sera were tested in the B-ELISA and I-ELISA, 31 ~ of animals were positive for BTV-specific antibody in the B-ELISA yet negative in the I-ELISA. This discrepancy between the two assays is partly due to potential problems with antibody titres to host cell proteins confusing the interpretation of low BTV-specific titres in the I-ELISA (Fig.  6a) . In addition, the B-ELISA has been shown to be much more sensitive to BTV-specific IgM produced early in infection (Fig. 5) . However 36~o of those sera positive in the B-ELISA and negative in the I-ELISA were positive in the EHD I-ELISA. This level of activity was significantly greater than the 16 ~ of EHD-positive sera found among sera negative in both the B-ELISA and the BTV I-ELISA. This increased EHD activity largely predominated in herd C alone (Table 5) . These results could suggest that the B-ELISA is sensitive to cross-reactive EHDspecific antibody present in test sera. However, because all experimental antisera to EHD serotypes tested failed to block the binding of 20E9B7G2 to BTV antigen (Table 4) , we suggest that the B-ELISA exhibits a much higher sensitivity for low antibody titres to BTV in field sera. The 34 B-ELISA-positive, BTV I-ELISA-negative sera which were positive in the EHD I-ELISA are more likely to be from animals from regions of high orbivirus activity and which have undergone separate infections with both BTV and EHD. Nine of the 21 EHD I-ELISApositive sera from herd C displayed high negative values (> 0.20 absorbance units) after their mock antigen reaction values had been accounted for (Table 5) , which may indicate low antibody titres to BTV that were just below the limits of sensitivity of the BTV I-ELISA were also present in these animals. In addition it may be possible that there was a particular, or potentially new, BTV type active in the region of some herds and that the BTV I-ELISA is relatively insensitive to it. The two field sera tested which were positive in the BTV I-ELISA and negative in the B-ELISA were probably from animals with a titre to EHD alone, which crossreacted in the BTV I-ELISA (Lunt et al., 1987) .
The B-ELISA employing MAbs is a test with enormous potential in serodiagnosis, not just for BTV but for any virus group where significant cross-reactivity can occur. The B-ELISA is independent of the species of origin of the antibody under test, relying only on an anti-mouse immunoglobulin conjugate, so that sera of different animals species may be incorporated in one assay. Using BTV serotype-specific MAbs (results not shown) we have applied the B-ELISA to serotyping, and achieved a test result that reflects neutralizing antibody levels in serum. The B-ELISA is more sensitive than the I-ELISA and displays much higher specificity than the AGDP test in which substantial cross-reactions between BTV and other orbiviruses may occur (DellaPorta et al., 1983a (DellaPorta et al., , 1985 . The B-ELISA has therefore much to recommend it as a standard screening method for serum antibodies to BTV.
